A phase I, open-label, multi-center, dose escalation study of the safety and pharmacokinetics of AGS-16M18 given as monotherapy in subjects with advanced renal cell carcinoma.
Phase of Trial: Phase I
Latest Information Update: 26 Feb 2013
At a glance
- Drugs AGS 16M18 (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Pharmacokinetics
- 26 May 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 25 Jun 2009 Planned end date changed from 1 Nov 2009 to 1 Nov 2010 as reported by ClinicalTrials.gov..
- 02 Jan 2009 New source identified and integrated (ClinicalTrials.gov record NCT00816686).